CodeTitleTypeCategory
TUPEB15 Ruxolitinib-mediated HIV-1 reservoir decay in A5336 phase 2a trialPoster exhibitionOther strategies and therapies
TUPEB16 Transformation of 3 current short-acting HIV drugs, tenofovir, lamivudine and dolutegravir (TLD) into a novel, all-in-one long-acting TLD 3-drug-combination in a single injectable dosage that produces extended pharmacokineticsPoster exhibitionOther strategies and therapies
TUPEB17 A biodegradable, subcutaneous implant delivery platform to treat HIV for up to 6 months in young childrenPoster exhibitionOther strategies and therapies
TUPEB18 Resistance to second generation integrase inhibitors after two years of a national rollout strategy in MexicoPoster exhibitionART resistance
TUPEB19 Doravirine Resistance Patterns Identified through week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 clinical trialsPoster exhibitionART resistance
TUPEB20 HIV viral suppression and drug resistance patterns among adults and children in the era of dolutegravir use: Findings from the national representative cross-sectional survey in TanzaniaPoster exhibitionART resistance
TUPEB21 CMV-Specific IgG changes during severe COVID-19 suggestive of acute reactivationPoster exhibitionSARS-CoV-2, COVID-19 and HIV
TUPEC01 A comparison of acceptability of HPV self-sampling for cervical cancer screening among women living with and without HIV in Lagos University Teaching Hospital, NigeriaPoster exhibitionSexual and reproductive health and HIV prevention
TUPEC02 Implementing cervical cancer screening tools to identify serotypes of human papillomavirus (HPV) among women living with HIV, Cuilapa Guatemala 2022Poster exhibitionSexual and reproductive health and HIV prevention
TUPEC03 Adoption of the Malkia Klabu prevention intervention in Tanzania for young women: distribution of HIV self-test kits and contraceptives at girl-friendly drug shopsPoster exhibitionSexual and reproductive health and HIV prevention
1341 - 1350 of 1427 items